Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases

Clinics in Chest Medicine

Volumn 31, Issue 3, 2010, Pages 565-588

  Meyer, Keith C ^a   Decker, Catherine ^b   Baughman, Robert ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b University of Wisconsin Health   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Adverse drug reactions; Autoimmunity; Connective tissue disease; Immunosuppressive drugs

Indexed keywords

ACTIVATED CARBON; ADALIMUMAB; ALLOPURINOL; ALUMINUM; AZATHIOPRINE; BUSULFAN; CHLOROQUINE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; FOLIC ACID; HYDROXYCHLOROQUINE; IMATINIB; INFLIXIMAB; IRON; LEFLUNOMIDE; MAGNESIUM SALT; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; AEROBIC EXERCISE; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANCA ASSOCIATED VASCULITIS; ANEMIA; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ANOREXIA; ANXIETY; APLASTIC ANEMIA; ASCITES; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AVASCULAR NECROSIS; BLADDER CANCER; BLEPHARITIS; BLOOD CELL COUNT; BLURRED VISION; BONE DENSITY; BONE MARROW SUPPRESSION; BONE PAIN; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHITIS; BURNING SENSATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CATARACT; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; CONFUSION; CONSTIPATION; CONVULSION; COUGHING; CROHN DISEASE; CUSHINGOID SYNDROME; CYTOPENIA; DEMYELINATING DISEASE; DERMATOMYOSITIS; DIABETES MELLITUS; DIARRHEA; DIPLOPIA; DISEASE SEVERITY; DIZZINESS; DRUG ACTIVITY; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; DYSPNEA; EOSINOPHILIA; ERYTHEMA MULTIFORME; ERYTHROCYTE APLASIA; EYE TOXICITY; FATIGUE; FIBROSING ALVEOLITIS; FIBROSIS; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL STROMAL TUMOR; GLAUCOMA; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HAIR DISCOLORATION; HEART ARREST; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART FUNCTION; HEMATURIA; HEMORRHAGIC CYSTITIS; HEPATITIS; HEPATITIS B; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INJECTION SITE REACTION; INSOMNIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KERATITIS; KIDNEY DISEASE; KIDNEY TUBULE NECROSIS; LEUKEMIA; LEUKOCYTOSIS; LEUKOPENIA; LICHENOID ERUPTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LUNG CANCER; LUNG DISEASE; LUNG EDEMA; LUNG FIBROSIS; LUNG TOXICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LUPUS LIKE SYNDROME; LYMPHOMA; MEGALOBLASTIC ANEMIA; MENTAL DISEASE; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; MYELODYSPLASTIC SYNDROME; MYOPATHY; NAIL DISEASE; NAUSEA; NECROTIZING FASCIITIS; NEOPLASM; NEPHROLITHIASIS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; PNEUMONIA; POLYMYOSITIS; POSTMARKETING SURVEILLANCE; PREGNANCY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PSORIATIC ARTHRITIS; QRS COMPLEX; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; RETINA MACULOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SERUM SICKNESS; SIDE EFFECT; SJOEGREN SYNDROME; SKIN ATROPHY; SKIN CANCER; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; STOMATITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; T WAVE; TACHYCARDIA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TOXIC MYOPATHY; TREMOR; TUBERCULOSIS; URINALYSIS; URINARY FREQUENCY; UROGENITAL TRACT DISEASE; URTICARIA; VAGINA BLEEDING; VAGINAL BURNING SENSATION; VASCULAR DISEASE; VASCULITIS; VASODILATATION; VISUAL DISORDER; VOMITING; WEGENER GRANULOMATOSIS;

EID: 77955380637     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.05.006     Document Type: Review

References (206)

1. Kourbeti I.S., Boumpas D. Biological therapies of autoimmune diseases. Curr Drug Targets Inflamm Allergy 2005, 4:41-46.
2. McDonough A.K., Curtis J.R., Saag K.G. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 2008, 20:131-137.
3. Lovell D.J., Giannini E.H., Reiff A., et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000, 342:763-769.
4. Kavanaugh A., Clair E.W., McCune W.J., et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000, 27:841-850.
5. Furst D.E., Schiff M.H., Fleischmann R.M., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003, 30:2563-2571.
6. Keystone E.C., Genovese M.C., Klareskog L., et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009, 68:789-796.
7. Goldenberg M.M. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther 1999, 21:75-87.
8. Weaver A. Efficacy and safety of the anti-TNF biologic agents. Mod Rheumatol 2004, 14:101-112.
9. Pham T., Claudepierre P., Deprez X., et al. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine 2005, 72(Suppl 1):S1-58.
10. Saag K.G., Teng G.G., Patkar N.M., et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784.
11. Smith C.H., Anstey A.V., Barker J.N., et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009, 161:987-1019.
12. Favalli E.G., Desiati F., Atzeni F., et al. Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:266-273.
13. Ramos-Casals M., Brito-Zeron P., Soto M.J., et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22:847-861.
14. Danila M.I., Patkar N.M., Curtis J.R., et al. Biologics and heart failure in rheumatoid arthritis: are we any wiser?. Curr Opin Rheumatol 2008, 20:327-333.
15. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
16. Fromont A., De Seze J., Fleury M.C., et al. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009, 45:55-57.
17. Reddy J., Loftus E. Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006, 35:837-855.
18. Strangfeld A., Listing J. Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 2006, 20:1181-1195.
19. Winthrop K., Siegel J., Jereb J., et al. Tuberculosis associated with therapy against tumor necrosis factor α. Arthritis Rheum 2005, 52(10):2978-2984.
20. Keane J., Gershon S., Wise R., et al. Tuberculosis associated with infliximab, a tumor necrosis factor-a-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
21. Gomez-Reino J., Carmona L., Valverde V., et al. on behalf of the DASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. A multicenter active-surveillance report. Arthritis Rheum 2003, 48(8):2122-2127.
22. Gardam M., Keystone E., Menzies R., et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003, 3:148-153.
23. Badesch D.B., Raskob G.E., Elliott C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2009, 137:376-387.
24. Available at:, Accessed December 5, 2009. http://www.remicade.com/remicade/assets/HCP_PPI.pdf.
25. Ledingham J., Deighton C., British Society for Rheumatology Standards GaAWGS Update on the British Society for Rheumatology guidelines for prescribing TNFa blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005, 44:157-163.
26. Chung E., Packer M., Lo K., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:2133-2140.
27. Peters M., Vis M., van Halm V., et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007, 66:958-961.
28. Allanore Y., Kahan A., Sellam J., et al. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin Chim Acta 2006, 365:143-148.
29. Mohan N., Edwards E., Cupps T., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001, 44:2862-2869.
30. Carroll M.B., Bond M.I. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008, 38(3):208-217.
31. Dixon W.G., Hyrich K.L., Watson K.D., et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2009, 69:522-528.
32. Baughman R.P., Lower E.E. Novel therapies for sarcoidosis. Semin Respir Crit Care Med 2007, 28:128-133.
33. Sandborn W.J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56:1232-1239.
34. Breedveld F.C., Weisman M.H., Kavanaugh A.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006, 54:26-37.
35. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
36. Tubach F., Ravaud P., Salmon-Ceron D., et al. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis 2006, 43:e95-100.
37. Kalyoncu U., Karaday O., Akdogan A., et al. Pneumocystic carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab. Scand J Infect Dis 2007, 39:475-478.
38. Stubgen J.P. Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 2008, 37:281-292.
39. Baghai M., Osmon D.R., Wolk D.M., et al. Fatal sepsis in a patient with rheumatoid arthritis treated with entanercept. Mayo Clin Proc 2001, 76:653-656.
40. Furst D.E., Breedveld F.C., Kalden J.R., et al. Updated consensus statement on biological agents, specifically tumour necrosis factor-alpha (TNF-alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2005, 64(Suppl 4):v2-14.
41. Mohan A.K., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
42. Kwon H.J., Cote T.R., Cuffe M.S., et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003, 138:807-811.
43. Daien C.I., Monnier A., Claudepierre P., et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford) 2009, 48(8):883-886.
44. Brown S.L., Greene M.H., Gershon S.K., et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002, 46:3151-3158.
45. Utz J.P., Limper A.H., Kalra S., et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003, 124:177-185.
46. Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751.
47. Wallis R.S., Broder M.S., Wong J.Y., et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004, 38:1261-1265.
48. Gomez-Reino J.J., Carmona L., Angel D.M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761.
49. Matulis G., Juni P., Villiger P.M., et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases performance of a mycobacterium tuberculosis antigen specific IFN-gamma assay. Ann Rheum Dis 2008, 67:84-90.
50. van der Kolk L.E., Baars J.W., Prins M.H., et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002, 100:2257-2259.
51. Dillman R.O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999, 18:465-471.
52. Schwartzberg L.S., Stepanski E.J., Fortner B.V., et al. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer 2008, 16:393-398.
53. Bennett C.M., Rogers Z.R., Kinnamon D.D., et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006, 107:2639-2642.
54. Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002, 70:329.
55. Wang J., Wiley J.M., Luddy R., et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005, 146:217-221.
56. Hellerstedt B., Ahmed A. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment. Ann Oncol 2003, 14:1792.
57. Carson K.R., Evens A.M., Richey E.A., et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113(20):4834-4840.
58. Fleischmann R.M. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009, 60(11):3225-3228.
59. Burton C., Kaczmarski R., Jan-Mohamed R., et al. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003, 348:2690-2691.
60. Herishanu Y., Polliack A., Leider-Trejo L., et al. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 2006, 6:407-409.
61. Lee Y., Kyung S.Y., Choi S.J., et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006, 21(3):183-186.
62. Fleischmann R.M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009, 38:265-280.
63. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992, 43:329-339.
64. Tiede I., Fritz G., Strand S., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003, 111:133-145.
65. Carrico C.K., Sartorelli A.C. Effects of 6-thioquanine on macromolecular events in regenerating rat liver. Cancer Res 1977, 37:1868-1875.
66. Stolk J.N., Boerbooms A.M., de Abreu R.A., et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998, 41(10):1858-1866.
67. Connell W.R., Kamm M.A., Ritchie J.K., et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993, 34:1081-1085.
68. Sturdevant R., Singleton J.W., Daren J.L., et al. Azathioprine-related pancreatitis in patients with Crohn's disease. Gastroenterology 1979, 77:883-886.
69. Dubinsky M.C., Vasiliauskas E.A., Singh H., et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298-303.
70. Kibukamusoke J.W. Malaria prophylaxis and immunosuppressant therapy in management of nephrotic syndrome associated with Guartan Malaria. Arch Dis Child 1968, 43:598.
71. Jeurissen M.E., Boerbooms A.M., van de Putte L.B. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 1988, 47:503-505.
72. Swanson M., Cook R. Drugs, chemicals, and blood dyscrasias 1977, Drug Intelligence Publications, Hamilton (IL).
73. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118:705-713.
74. Cuffari C., Theoret Y., Latour S., et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996, 39:401-406.
75. Kirschner B.S. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998, 115:813-821.
76. Rundles R.W., Wyngaarden J.B., Hitchings G.H. Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout. Trans Assoc Am Physicians 1963, 76:126.
77. Gossman J., Kachel H.G., Schoepe W., et al. Anemia in renal transplant recipients caused by concomitant therapy with azathioprine and angiotensin-converting enzyme inhibitors. Transplantation 1993, 56:585-589.
78. Gaffney K., Scott D.G. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol 1998, 37:824-836.
79. Baughman R.P., Peddi R., Lower E.E. Therapy: general issues. Diffuse lung disease: a practical approach 2004, 78-105. Arnold, London. R.P. Baughman, R.M. du Bois, J.P. Lynch (Eds.).
80. Tashkin D.P., Elashoff R., Clements P.J., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
81. Hoyles R.K., Ellis R.W., Wellsbury J., et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006, 54:3962-3970.
82. Kondoh Y., Taniguchi H., Yokoi T., et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. Eur Respir J 2005, 25:528-533.
83. Baughman R.P., Lower E.E. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992, 102:1090-1094.
84. Haubitz M., Schellong S., Gobel U., et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998, 41:1835-1844.
85. Adu D., Pall A., Luqmani R.A., et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997, 90:401-409.
86. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996, 124:477-484.
87. Radis C.D., Kahl L.E., Baker G.L., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum 1995, 38:1120-1127.
88. Martin-Suarez I., D'Cruz D., Mansoor M., et al. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997, 56:481-487.
89. Martin F., Lauwerys B., Lefebvre C., et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997, 6:254-257.
90. de Groot K., Adu D., Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol Dial Transplant 2001, 16:2018-2027.
91. Dorr F.A., Coltman C.A. Second cancers following antineoplastic therapy. Curr Probl Cancer 1985, 9:1-43.
92. Knight A., Askling J., Ekbom A. Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis. Int J Cancer 2002, 100:82-85.
93. Hesselstrand R., Scheja A., Akesson A. Mortality and causes of death in a Swedish series of systemic sclerosis patients. Ann Rheum Dis 1998, 57:682-686.
94. Girling D.J., Stott H., Stephens R.J., et al. Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma. Br J Cancer 1985, 52:867-873.
95. Siemann D.W., Macler L., Penney D.P. Cyclophosphamide-induced pulmonary toxicity. Br J Cancer Suppl 1986, 7:343-346.
96. Gould V.E., Miller J. Sclerosing alveolitis induced by cyclophosphamide. Ultrastructural observations on alveolar injury and repair. Am J Pathol 1975, 81:513-553.
97. Malik S.W., Myers J.L., DeRemee R.A., et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996, 154:1851-1856.
98. Stott H., Stephens R., Fox W., et al. An investigation of the chest radiographs in a controlled trial of busulphan, cyclophosphamide, and a placebo after resection for carcinoma of the lung. Thorax 1976, 31:265-270.
99. Baughman R.P., Winget D.B., Lower E.E. Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial. Sarcoidosis Vasc Diffuse Lung Dis 2000, 17:60-66.
100. Lower E.E., Baughman R.P. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990, 299:153-157.
101. de Groot K., Rasmussen N., Bacon P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461-2469.
102. de Groot K., Reinhold-Keller E., Tatsis E., et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996, 39:2052-2061.
103. Douglas W.W., Tazelaar H.D., Hartman T.E., et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001, 164(7):1182-1185.
104. Chan E.S., Cronstein B.N. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002, 4(4):266-273.
105. Montesinos M.C., Desai A., Delano D., et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003, 48:240-247.
106. Montesinos M.C., Yap J.S., Desai A., et al. Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis. Arthritis Rheum 2000, 43:656-663.
107. Weinblatt M.E., Coblyn J.S., Fox D.A., et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985, 312:818-822.
108. Wijnands M.J., van Riel P.L., Gribnau F.W., et al. Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. Semin Arthritis Rheum 1990, 19:337-352.
109. McKendry R.J., Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993, 20:1850-1856.
110. Kinder A.J., Hassell A.B., Brand J., et al. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford) 2005, 44:61-66.
111. McKendry R.J., Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis: a case-control study of 131 patients. Arch Intern Med 1989, 149:685-689.
112. Hargreaves M.R., Mowat A.G., Benson M.K. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax 1992, 47(8):628-633.
113. Salaffi F., Manganelli P., Carotti M., et al. Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 1997, 16:296-304.
114. Zisman D.A., McCune W.J., Tino G., et al. Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis Vasc Diffuse Lung Dis 2001, 18:243-252.
115. Dawson J.K., Graham D.R., Desmond J., et al. Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests. Rheumatology (Oxford) 2002, 41:262-267.
116. Roenigk H.H., Auerbach R., Mailbach H.I., et al. Methotrexate guidelines revised. J Am Acad Dermatol 1982, 6:145-155.
117. Whiting-O'Keefe Q.E., Fye K.H., Sack K.D. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90:711-716.
118. Kremer J.M., Alarcon G.S., Lightfoot R.W., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994, 37(3):316-328.
119. Walker A.M., Funch D., Dreyer N.A., et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum 1993, 36(3):329-335.
120. Evans W.E., Pratt C.B. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978, 23:68-72.
121. Li J., Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol 2002, 50(5):373-382.
122. Evans W.E., Tsiatis A., Crom W.R., et al. Pharmacokinetics of sustained serum methotrexate concentrations secondary to gastrointestinal obstruction. J Pharm Sci 1981, 70:1194-1198.
123. Morgan S.L., Baggott J.E., Vaughn W.H., et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. Ann Intern Med 1994, 121:833-841.
124. van Ede A.E., Laan R.F., Rood M.J., et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2001, 44:1515-1524.
125. Pavy S., Constantin A., Pham T., et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006, 73:388-395.
126. Baughman R.P., Lower E.E. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999, 54:742-746.
127. Ortiz-Alvarez O., Morishita K., Avery G., et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004, 31:2501-2506.
128. Aithal G.P., Haugk B., Das S., et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. Aliment Pharmacol Ther 2004, 19:391-399.
129. Erickson A.R., Reddy V., Vogelgesang S.A., et al. Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum 1995, 38:1115-1119.
130. Smolen J.S., Kalden J.R., Scott D.L., et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999, 353:259-266.
131. Emery P., Breedveld F.C., Lemmel E.M., et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:655-665.
132. Cohen S., Cannon G.W., Schiff M., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001, 44:1984-1992.
133. Strand V., Cohen S., Schiff M., et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999, 159:2542-2550.
134. Nash P., Thaci D., Behrens F., et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 2006, 212:238-249.
135. van Woerkom J., Kruize A.A., Geenen R., et al. Safety and efficacy of Leflunomide in primary Sjögren's syndrome: a phase II pilot study. Ann Rheum Dis 2007, 66:1026-1032.
136. Tam L.S., Li E.K., Wong C.K., et al. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004, 13:601-604.
137. van Denderen J.C., van der Paardt M., Nurmohamed M.T., et al. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005, 64:1761-1764.
138. Metzler C., Fink C., Lamprecht P., et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004, 43:315-320.
139. Lange U., Piegsa M., Muller-Ladner U., et al. Anti-Jo-1 antibody positive polymyositis-successful therapy with leflunomide. Autoimmunity 2006, 39:261-264.
140. Handler R.P. Leflunomide for relapsing polychondritis: successful longterm treatment. J Rheumatol 2006, 33:1916-1917.
141. Pirildar T. Treatment of adult-onset Still's disease with leflunomide and chloroquine combination in two patients. Clin Rheumatol 2003, 22:157.
142. Sebastiani M., Giuggioli D., Vesprini E., et al. Successful treatment with leflunomide of arthritis in systemic sclerosis patients. Rheumatology (Oxford) 2006, 45:1175-1176.
143. Cherwinski H.M., Cohn R.G., Cheung P., et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995, 275:1043-1049.
144. Li E.K., Tam L.S., Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 2004, 26:447-459.
145. Perez-Ruiz F., Nolla J.M. Influence of Leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. J Clin Rheumatol 2003, 9:215-218.
146. Prakash A., Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999, 58:1137-1164.
147. Olsen N.J., Stein C.M. New drugs for rheumatoid arthritis. N Engl J Med 2004, 350:2167-2179.
148. Bharadwaj A., Haroon N. Peripheral neuropathy in patients on leflunomide. Rheumatology (Oxford) 2004, 43:934.
149. Bonnel R.A., Graham D.J. Peripheral neuropathy in patients treated with leflunomide. Clin Pharmacol Ther 2004, 75:580-585.
150. Richards B.L., Spies J., McGill N., et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J 2007, 37(2):101-107.
151. Takeishi M., Akiyama Y., Akiba H., et al. Leflunomide induced acute interstitial pneumonia. J Rheumatol 2005, 32:1160-1163.
152. Sakai F., Noma S., Kurihara Y., et al. Leflunomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol 2005, 15:173-179.
153. Suissa S., Hudson M., Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006, 54:1435-1439.
154. Allison A.C., Eugui E.M. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol 1993, 14:353-380.
155. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350:971-980.
156. Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993, 11(Suppl 8):S117-S119.
157. Langford C.A., Talar-Williams C., Sneller M.C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004, 15:278-283.
158. Samad A.S., Lindsley C.B. Treatment of pulmonary hemorrhage in childhood systemic lupus erythematosus with mycophenolate mofetil. South Med J 2003, 96:705-707.
159. Swigris J.J., Olson A.L., Fischer A., et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest 2006, 130:30-36.
160. Staatz C.E., Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007, 46:13-58.
161. Parker G., Bullingham R., Kamm B., et al. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996, 36:332-344.
162. Nogueras F., Espinosa M.D., Mansilla A., et al. Mycophenolate mofetil-induced neutropenia in liver transplantation. Transplant Proc 2005, 37(3):1509-1511.
163. Warrington J.S., Shaw L.M. Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy. Curr Opin Drug Metab Toxicol 2005, 1:487-503.
164. Morii M., Ueno K., Ogawa A., et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000, 68:613-616.
165. Smith K.G., Isbel N.M., Catton M.G., et al. Suppression of the humoral immune response by mycophenolate mofetil. Nephrol Dial Transplant 1998, 13:160-164.
166. Kaczmarek I, Bigdeli AK, Vogeser M, et al. Defining algorithms for efficient therapeutic drug monitoring of mycophenolate mofetil in heart transplant recipients. Ther Drug Monit 2008, 30:419-427.
167. Meiser B.M., Pfeiffer M., Schmidt D., et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999, 18:143-149.
168. van Gelder T., le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006, 28:145-154.
169. Filler G., Ehrich J. Mycophenolate mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration. Nephrol Dial Transplant 1997, 12:374-375.
170. van Gelder T., Silva H.T., de Fijter J.W., et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008, 86(8):1043-1051.
171. Furst D.E. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus 1996, 5(Suppl 1):S11-S15.
172. Tett S.E. Clinical pharmacokinetics of slow-acting antirheumatic drugs. Clin Pharmacokinet 1993, 25:392-407.
173. Estes M.L., Ewing-Wilson D., Chou S.M., et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987, 82:447-455.
174. Ratiff N.B., Estes M.L., Myles J.L., et al. Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy. N Engl J Med 1987, 316:191-193.
175. Brachman P.S., Metchock B., Kozarsky P.E. Effects of antimalarial chemoprophylactic agents on the viability of the Ty21a typhoid vaccine strain. Clin Infect Dis 1992, 15:1057-1058.
176. Horowitz H., Carbonaro C.A. Inhibition of the Salmonella typhi oral vaccine strain, Ty21a, by mefloquine and chloroquine. J Infect Dis 1992, 166:1462-1464.
177. Pappaioanou M., Fishbein D.B., Dreesen D.W., et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986, 314:280-284.
178. Rennie I.G. Clinically important ocular reactions to systemic drug therapy. Drug Saf 1993, 9:196-211.
179. Elder M., Rahman A.M., McLay J. Early paracentral visual field loss in patients taking hydroxychloroquine. Arch Ophthalmol 2006, 124:1729-1733.
180. Yam J.C., Kwok A.K. Ocular toxicity of hydroxychloroquine. Hong Kong Med J 2006, 12:294-304.
181. Mazzuca S.A., Yung R., Brandt K.D., et al. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy. J Rheumatol 1994, 21:59-63.
182. Daniels C.E., Wilkes M.C., Edens M., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316.
183. Ghofrani H.A., Seeger W., Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353:1412-1413.
184. Patterson K.C., Weissmann A., Ahmadi T., et al. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006, 145:152-153.
185. van Glabbeke M., Verweij J., Casali P.G., et al. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). Eur J Cancer 2006, 42:2277-2285.
186. Hensley M.L., Ford J.M. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003, 40:21-25.
187. Chintalgattu V., Patel S.S., Khakoo A.Y. Cardiovascular effects of tyrosine kinase inhibitors used to gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009, 23:97-107.
188. Yamasawa H., Sugiyama Y., Bando M., et al. Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration 2008, 75:350-354.
189. Yokoyama T., Miyazawa K., Kurakawa E., et al. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004, 18:645-646.
190. Ostensen M., Lockshin M., Doria A., et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008, 47(Suppl 3):iii28-iii31.
191. Miniero R., Tardivo I., Curtoni E.S., et al. Pregnancy after renal transplantation in Italian patients: focus on fetal outcome. J Nephrol 2002, 15(6):626-632.
192. Ostensen M., Ramsey-Goldman R. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?. Drug Saf 1998, 19(5):389-410.
193. Weber L.T., Shipkova M., Lamersdorf T., et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998, 9:1511-1520.
194. Mori M., Naruto T., Imagawa T., et al. Methotrexate for the treatment of juvenile idiopathic arthritis: process to approval for JIA indication in Japan. Mod Rheumatol 2006, 19:1-11.
195. Sarwal M., Pascual J. Immunosuppression minimization in pediatric transplantation. Am J Transplant 2007, 7:2227-2235.
196. Sarwal M.M. Out with the old, in with the new: immunosuppresion minimization in children. Curr Opin Organ Transplant 2008, 13:513-521.
197. Dubinsky M.C., Reyes E., Ofman J., et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005, 100:2239-2247.
198. Godeau B., Coutant-Perronne V., Le Thi Huong D., et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994, 21:246-251.
199. Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996, 71:5-13.
200. Sen R.P., Walsh T.E., Fisher W., et al. Pulmonary complications of combination therapy with cyclophosphamide and prednisone. Chest 1991, 99:143-146.
201. Rodriguez M., Fishman J.A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004, 17:770-782.
202. Ogawa J., Harigai M., Nagasaka K., et al. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium- or high-dose corticosteroid therapy. Mod Rheumatol 2005, 15:91-96.
203. Bedrossian C.W., Sussman J., Conklin R.H., et al. Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol 1984, 82:148-154.
204. Gross D.C., Sasaki T.M., Buick M.K., et al. Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation 1997, 64:1607-1609.
205. Rosado M.F., Donna E., Ahn Y.S. Challenging problems in advanced malignancy. Case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003, 21:3171-3173.
206. Available at:, Accessed December 5, 2009. http://www.pneumotox.com.